These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 26967743)

  • 1. A review of antidepressant-induced urinary hesitancy: a focus on levomilnacipran ER including two case presentations(5633).
    Asnis GM; Caneva E; Henderson MA
    Expert Opin Drug Saf; 2016 May; 15(5):717-25. PubMed ID: 26967743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder.
    Blum SI; Tourkodimitris S; Ruth A
    J Affect Disord; 2015 Jan; 170():230-6. PubMed ID: 25259674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levomilnacipran (Fetzima): A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder.
    Saraceni MM; Venci JV; Gandhi MA
    J Pharm Pract; 2014 Aug; 27(4):389-95. PubMed ID: 24381243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of levomilnacipran extended release in treating major depressive disorder.
    Ragguett RM; Yim SJ; Ho PT; McIntyre RS
    Expert Opin Pharmacother; 2017 Dec; 18(18):2017-2024. PubMed ID: 29195487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2013 Nov; 67(11):1089-104. PubMed ID: 24016209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review.
    Bruno A; Morabito P; Spina E; Muscatello MR
    Curr Neuropharmacol; 2016; 14(2):191-9. PubMed ID: 26572745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.
    Deardorff WJ; Grossberg GT
    Expert Opin Pharmacother; 2014 Dec; 15(17):2525-42. PubMed ID: 25224953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials.
    Sambunaris A; Gommoll C; Chen C; Greenberg WM
    Int Clin Psychopharmacol; 2014 Jul; 29(4):197-205. PubMed ID: 24667487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans.
    Chen L; Greenberg WM; Brand-Schieber E; Wangsa J; Periclou A; Ghahramani P
    Drug Des Devel Ther; 2015; 9():3293-300. PubMed ID: 26150701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vortioxetine (Brintellix®) and levomilnacipran (Fetzima®): the two newest additions to the antidepressant formulary.
    Roman MW; Wilkinson SM
    Issues Ment Health Nurs; 2014 Dec; 35(12):972-4. PubMed ID: 25426751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder.
    Scott LJ
    CNS Drugs; 2014 Nov; 28(11):1071-82. PubMed ID: 25270036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
    Montgomery SA; Mansuy L; Ruth A; Bose A; Li H; Li D
    J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition.
    Chen L; Greenberg WM; Gommoll C; O'Connor J; Zukin SR; Periclou A; Ghahramani P
    Clin Ther; 2015 Sep; 37(9):2059-70. PubMed ID: 26256429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fetzima (levomilnacipran), a drug for major depressive disorder as a dual inhibitor for human serotonin transporters and beta-site amyloid precursor protein cleaving enzyme-1.
    Rizvi SM; Shaikh S; Khan M; Biswas D; Hameed N; Shakil S
    CNS Neurol Disord Drug Targets; 2014; 13(8):1427-31. PubMed ID: 25345508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study.
    Mago R; Forero G; Greenberg WM; Gommoll C; Chen C
    Clin Drug Investig; 2013 Oct; 33(10):761-71. PubMed ID: 23999912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levomilnacipran: a newly approved drug for treatment of major depressive disorder.
    Mago R; Mahajan R; Thase ME
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):137-45. PubMed ID: 24524592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levomilnacipran extended release: first global approval.
    Hair P; Cameron F; Garnock-Jones KP
    Drugs; 2013 Sep; 73(14):1639-45. PubMed ID: 24000002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamsulosin as an effective treatment for reboxetine-associated urinary hesitancy.
    Demyttenaere K; Huygens R; Van Buggenhout R
    Int Clin Psychopharmacol; 2001 Nov; 16(6):353-5. PubMed ID: 11712624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder.
    Thase ME; Gommoll C; Chen C; Kramer K; Khan A; Durgam S
    CNS Spectr; 2017 Dec; 22(6):475-483. PubMed ID: 28521846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LEVOMILNACIPRAN--A SUCCESSOR OF MILNACIPRAN WITH A HIGHER NORADRENERGIC SELECTIVITY.
    Zadka Ł; Dziwota E; Olajossy M
    Acta Pol Pharm; 2016; 73(2):285-9. PubMed ID: 27180420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.